[Neuroleptic malignant syndrome].
The neuroleptic malignant syndrome (NMS) is a rare but potentially lethal form of neuroleptic drug-induced hyperthermia, altered level of consciousness, extrapyramidal effects, autonomic instability and muscle rigidity. The present review describes pathophysiology, frequency, course, outcome, mortality and management of NMS in prehospital care and emergency department care. Review discusses clinical features, diagnosis differentiation of this hyperpyretic-rigidity syndrome from other disorders and prevention of this serious iatrogenic condition as life-threatening disorder.
Reingardiene
Dagmara
D
Kauno medicinos universiteto Intensyviosios terapijos klinika, Eiveniu 2, 3007 Kaunas.
D058186:Acute Kidney Injury / Q000209:etiology; D000328:Adult; D000547:Amantadine / Q000008:administration & dosage / Q000627:therapeutic use; D001971:Bromocriptine / Q000008:administration & dosage / Q000627:therapeutic use; D002230:Carbidopa / Q000008:administration & dosage / Q000627:therapeutic use; D000075202:Contraindications; D003620:Dantrolene / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D011379:Prognosis; D012206:Rhabdomyolysis / Q000209:etiology
D015259:Dopamine Agents; D018491:Dopamine Agonists; D009125:Muscle Relaxants, Central; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine; D003620:Dantrolene; D002230:Carbidopa